View study details on clinicaltrials.gov.
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes in patients with relapsing multiple sclerosis transitioning from dimethyl fumarate or fingolimod therapy.
Location: PAMF (Peninsula/South Bay/Santa Cruz)
Please contact: Renee Kaneshiro at email@example.com about Artios
Minal Bhanushali, MD, PAMFRI Medical Director, Ariele L Greenfield, M.D., Director of PAMF Multiple Sclerosis Center
Investigator: Lawrence Dickinson, M.D
Using Electronic Health Records to Identify Gaps in Migraine Headache Care: A Step Towards Improving Patient Outcomes
Mindfulness and Migraine: A Randomized Controlled Trial
Investigator: Sylvia Sudat, PhD